^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LB1410

    i
    Other names: Bis-5, LB1410, Bis5, BIS-5, LNL005, BIS 5, LB 1410, LNL 005, LB-1410, LNL-005, BIS5
    Associations

    News

    Trials
    Company:
    L&L Biopharma
    Drug class:
    PD1 inhibitor, TIM-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    TRIGGERCD8: A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=194, Recruiting, L & L biopharma Co., Ltd., Shanghai China | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    LB1410 • LB4330
    6ms
    TRIGGERCD8: A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=194, Not yet recruiting, L & L biopharma Co., Ltd., Shanghai China
    New P1/2 trial • Combination therapy • Metastases
    |
    LB1410 • LB4330
    almost2years
    A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001） (clinicaltrials.gov)
    P1, N=100, Recruiting, L & L biopharma Co., Ltd., Shanghai China | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    LB1410
    over2years
    A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001） (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, L & L biopharma Co., Ltd., Shanghai China
    New P1 trial
    |
    HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    LB1410